Dynavax Board Unanimously Recommends Sanofi's $15.50/Share All-Cash Tender Offer for Acquisition

summarizeSummary

Sanofi is acquiring Dynavax Technologies Corporation for $15.50 per share in an all-cash tender offer, a transaction unanimously recommended by Dynavax's Board of Directors.

check_boxKey Events

• Acquisition Agreement

  Sanofi, through its subsidiary Samba Merger Sub, Inc., is acquiring Dynavax Technologies Corporation for $15.50 per share in an all-cash tender offer.

• Board Recommendation

  Dynavax's Board of Directors unanimously recommends that shareholders tender their shares, citing the offer as advisable and in the best interest of the company and its stockholders.

• Significant Premium

  The $15.50 per share offer price represents a premium of approximately 39% to Dynavax's closing price on December 23, 2025, and 46% to the 90-day volume-weighted average price. The offer price is also near the stock's 52-week high of $15.49.

• Certainty of Value

  The all-cash consideration provides immediate and certain value to shareholders, mitigating risks associated with Dynavax's standalone strategy and pipeline development.

auto_awesomeAnalysis

The SC 14D9 filing confirms that Dynavax Technologies Corporation's Board of Directors unanimously recommends shareholders accept Sanofi's all-cash tender offer of $15.50 per share. This acquisition provides immediate and certain value to Dynavax shareholders, representing a substantial premium of approximately 39% to the stock's closing price on December 23, 2025, and 46% to the 90-day volume-weighted average price. The board's decision follows an extensive evaluation of strategic alternatives and negotiations, concluding that Sanofi's offer represents the best available option for maximizing shareholder value. The all-cash nature and the structure as a tender offer followed by a short-form merger indicate a high likelihood of timely consummation, offering a clear exit for investors near the stock's 52-week high.